Evidence map›Paper›PMID 29143678›Full record

ArticleParasites & vectors2017

Shifting the paradigm in Dirofilaria immitis prevention: blocking transmission from mosquitoes to dogs using repellents/insecticides and macrocyclic lactone prevention as part of a multimodal approach.

John W McCall, Marie Varloud, Elizabeth Hodgkins, Abdelmoneim Mansour, Utami DiCosty, Scott McCall, James Carmichael, Ben Carson, Justin Carter

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Travelling safe? Risks associated toCurrent research in parasitology & vector-borne diseases · 2025
    Article
  6. Article
  7. New distribution patterns ofFrontiers in veterinary science · 2023
    Article
  8. Article
  9. Heartworm disease - Overview, intervention, and industry perspective.International journal for parasitology. Drugs and drug resistance · 2021
    Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

John W McCallTRS Labs, Inc., 215 Paradise Boulevard, Athens, GA, 30607, USA. jwmccall@uga.edu.
Marie VarloudCeva Santé Animale, Libourne, France.
Elizabeth HodgkinsCeva Animal Health, Lenexa, Kansas, USA.
Abdelmoneim MansourTRS Labs, Inc., 215 Paradise Boulevard, Athens, GA, 30607, USA.
Utami DiCostyTRS Labs, Inc., 215 Paradise Boulevard, Athens, GA, 30607, USA.
Scott McCallTRS Labs, Inc., 215 Paradise Boulevard, Athens, GA, 30607, USA.
James CarmichaelTRS Labs, Inc., 215 Paradise Boulevard, Athens, GA, 30607, USA.
Ben CarsonTRS Labs, Inc., 215 Paradise Boulevard, Athens, GA, 30607, USA.
Justin CarterTRS Labs, Inc., 215 Paradise Boulevard, Athens, GA, 30607, USA.
Département Santé Animale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study assessed the influence of a topical ectoparasiticide (dinotefuran-permethrin-pyriproxyfen, DPP, Vectra® 3D, Ceva Animal Health) combined with a macrocyclic lactone (milbemycin oxime, MBO, Interceptor®, Virbac) on transmission of heartworm L3 from mosquitoes to dogs and subsequent development of worms in treated dogs exposed to infected mosquitoes.

methodsThirty-two beagle dogs were allocated to four groups of eight: Group 1, untreated controls; Group 2, treated topically with DPP on Day 0; Group 3, treated orally with MBO on Day 51; and Group 4, treated with DPP on Day 0 and MBO on Day 51. Dogs were exposed under sedation for 1 h to Dirofilaria immitis (JYD-34)-infected Aedes aegypti on Days 21 and 28. At the end of each exposure, mosquitoes were classified as live, moribund, or dead and engorged or non-engorged. Live or moribund mosquitoes were incubated for daily survival assessment for 3 days. Mosquitoes were dissected before and after exposure to estimate the number of L3 transmitted to each dog. Dogs were necropsied 148 to 149 days postinfection.

resultsA total of 418 mosquitoes fed on the 16 dogs in Groups 1 and 3, while only 6 fed on the 16 DPP-treated dogs in Groups 2 and 4. Mosquito anti-feeding (repellency) effect in Groups 2 and 4 was 98.1 and 99.1%, respectively. The estimated numbers of L3 transmitted to controls, DPP-treated, MBO-treated and DPP + MBO-treated dogs were 76, 2, 78, and 1, respectively. No heartworms were detected in any of the DPP + MBO-treated dogs (100% efficacy), while 8 out of 8 were infected in the control group (range, 21-66 worms per dog), 8 out of 8 were infected in the MBO-treated group (58% efficacy), and 3 out of 8 were infected in the DPP-treated group (96% efficacy).

conclusionsDPP repelled and killed most mosquitoes that were capable of transmitting heartworm L3 to dogs. The "Double Defense" protocol of DPP + MBO had better efficacy for protecting dogs against heartworm transmission and infection than MBO alone. This added DPP benefit is more pronounced when macrocyclic lactone-resistant strains of heartworms are involved or lack of compliance in macrocyclic lactone administration is known or suspected.

Indexed as

AedesAnimalsDirofilaria immitisDirofilariasisDog DiseasesDogsFemaleFilaricidesInsecticidesInsect RepellentsInsect VectorsLactonesMaleFilaricidesInsecticidesInsect RepellentsLactonesDirofilaria immitisInfectionLethal repellencyMosquitoesPrevention strategyVector

Identifiers

PMID29143678
PMCPMC5688480
OpenAlexW2767902250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.